Siplizumab

希普利珠单抗

Report date: 2026/04/29 20:02:18

Base Information

Drug NameSiplizumab
Drug Alias NameMEDI-507TCD-601
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionT-cell surface antigen CD2 inhibitors
TargetsT-cell surface antigen CD2
Therapy Area/IndicationsPlaque psoriasisRejection of renal transplantationGraft vs Host Disease +[24] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[9] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesCatholic University Of LouvainItb-Med Llc
China Registration ClassN/A

Develop Information

Active CompaniesItb-Med LlcNefro Avillion Clinical Development LLCUniversity Of Alabama At Birmingham
Inactive CompaniesDana-Farber Cancer InstituteColumbia UniversityNational Cancer Institute +[5] 
Active IndicationsRejection of renal transplantationRenal InsufficiencyAmyotrophic Lateral Sclerosis +[10] 
Inactive IndicationsPlaque psoriasisGraft vs Host DiseaseDiabetes Mellitus, Type 1 +[14] 

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG